Halozyme Therapeutics, INC Form 4 insider transactions

Bernadette Connaughton, a Director of Halozyme Therapeutics, Inc., sold 1,626 shares of common stock on August 10, 2026 for $102.80 per share.

Halozyme Therapeutics President and CEO Helen Torley executed a series of stock transactions on July 8, 2026, including the exercise of stock options and the sale of common stock, all conducted under a pre-established Rule 10b5-1 trading plan.

Halozyme Therapeutics EVP David A. Ramsay reports transactions involving common stock, restricted stock units, and stock options.

Darren Snellgrove, SVP and CFO of Halozyme Therapeutics, has been granted restricted stock units and stock options, with specific vesting schedules outlined.

Halozyme Therapeutics Director Bernadette Connaughton has sold a total of 1,625 shares of common stock under a pre-arranged trading plan.

Halozyme Therapeutics director Mahesh Krishnan executed a 10b5-1 plan, acquiring 7,304 shares at $38.46 and selling 7,304 shares at $75.

Mark Howard Snyder, SVP and Chief Legal Officer of Halozyme Therapeutics, Inc., reported transactions involving common stock and restricted stock units.

Halozyme Therapeutics CEO Helen Torley exercised 50,000 stock options and sold the resulting shares under a 10b5-1 trading plan.

Halozyme Therapeutics director Bernadette Connaughton sold 1,625 shares of common stock on June 1, 2026.

Halozyme Therapeutics CEO Helen Torley exercised 50,000 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

Director Matthew L. Posard received an annual grant of 3,796 restricted stock units and 6,040 stock options as part of Halozyme Therapeutics' director compensation program.

Director Mahesh Krishnan was granted 3,796 restricted stock units and 6,040 stock options as part of Halozyme Therapeutics' annual director compensation program.

Director James Paul Lang received an annual grant of restricted stock units and stock options as part of Halozyme Therapeutics' director compensation program.

Director Jeffrey William Henderson received an annual grant of 3,796 restricted stock units and 6,040 stock options as part of the company's director compensation program.

Director Barbara Gayle Duncan received an annual grant of 3,796 restricted stock units and 6,040 stock options as part of Halozyme Therapeutics' director compensation program.

Director Bernadette Connaughton received an annual grant of restricted stock units and stock options as part of Halozyme Therapeutics' director compensation program.

Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics common stock at $63.48 per share.

Halozyme Therapeutics President and CEO Helen Torley reported transactions involving the acquisition and sale of company stock, executed under a pre-arranged trading plan.

Halozyme Therapeutics, Inc. reports an interim CFO, David A. Ramsay, received a stock award of 10,000 units.

Halozyme Therapeutics President and CEO Helen Torley executed a series of stock transactions, including option exercises and sales, under a pre-arranged 10b5-1 trading plan.

Halozyme Therapeutics CEO Helen Torley executed a series of planned stock option exercises and subsequent sales of common stock totaling 50,000 shares.

Halozyme Therapeutics' COO, Cortney Caudill, reported the vesting of restricted stock units and subsequent sale of shares for tax obligations.

Halozyme Therapeutics' SVP, Chief Legal Officer, Mark Howard Snyder, reported the vesting of restricted stock units and subsequent share dispositions for tax obligations.

Halozyme Therapeutics' CFO, Nicole LaBrosse, reported the vesting of restricted and performance stock units, along with corresponding share dispositions for tax obligations.

Halozyme Therapeutics CEO Helen Torley reported routine stock transactions related to restricted stock unit vesting and tax withholdings.

Halozyme Therapeutics' Chief Operating Officer, Cortney Caudill, received significant equity awards including stock options, restricted stock units, and performance stock units.

Halozyme Therapeutics' SVP, Chief Legal Officer, Mark Howard Snyder, acquired significant equity awards including stock options, restricted stock units, and performance stock units.

Halozyme Therapeutics' SVP and Chief Financial Officer, Nicole LaBrosse, was awarded performance-based stock units following the determination of performance period vesting.

Halozyme Therapeutics' President and CEO, Helen Torley, received significant equity awards including stock options, restricted stock units, and performance stock units.

Halozyme Therapeutics CEO Helen Torley exercised stock options and subsequently sold common shares in pre-planned transactions.